Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialÉric Pujade-Lauraine, Thibault De La Motte Rouge, Jonathan A. Ledermann et al.|The Lancet Oncology|2017Cited by 1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Jae‐Hoon Kim et al.|The Lancet Oncology|2021Cited by 412
Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation CarriersFergus J. Couch, Theo A. van Os, Mia M. Gaudet et al.|Cancer Epidemiology Biomarkers & Prevention|2012Cited by 57
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyIrma Kluijt, Anna Jakubowska, Dominik Rozkrut et al.|British Journal of Cancer|2012Cited by 38
Data from Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation CarriersFergus J. Couch, Theo A. van Os, Mia M. Gaudet et al.|Unknown|2023Cited by 0